ADAM17 and breast carcinoma: In breast carcinoma cells, ERK or p38 signalling induces TACE activation by increasing the presentation of TACE on cell surfaces and decreasing the inhibition of TACE activation by tissue inhibitor of metalloproteinase-3 (TIMP3) [39].